Alembic Pharmaceuticals Limited (Aplltd) (NSE: APLLTD, BSE: 533573) is a Vadodara, Gujarat-based company in the Non-Prescription Drugs industry. With a market capitalisation of ₹20,245 Cr, it ranks #371 by market cap among the 6,197 Indian listed companies on FinBizNet, and #2 of 9 in Non-Prescription Drugs. At ₹1,030.00 (as of 16 Nov 2026), the share price is 4.0% below its 52-week high of ₹1,073.00 and 62.0% above its 52-week low of ₹635.80. The share price is up 11.7% over one year and up 23.9% over three months.
| Current Price | ₹1,030.00 |
|---|---|
| Market Cap | ₹20,245 Cr |
| NSE Symbol | APLLTD |
| BSE Code | 533573 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Non-Prescription Drugs |
| P/E Ratio | 30.5 |
| Return on Equity | 12.36% |
| Return on Assets | 6.03% |
| 52-Week Range | ₹635.80 – ₹1,073.00 |
| 1-Year Price Change | +11.7% |
| 3-Month Price Change | +23.9% |
| Beta (1Y) | 0.06 |
| Dividend Yield | 1.15% |
| Headquarters | Vadodara, Gujarat |
| Website | alembicpharmaceuticals.com |
| Revenue | ₹2,603 Cr |
|---|---|
| Net Profit | ₹334 Cr |
| Net Margin | 12.8% |
| EPS (Basic) | ₹17.05 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Alembic Pharmaceuticals Limited (Aplltd) reported revenue of ₹2,603 Cr in Q2 FY27, up 36.3% from ₹1,910 Cr in Q2 FY26 and up 21.1% from ₹2,150 Cr in Q1 FY27. It posted a net profit of ₹334 Cr for the quarter, against a net profit of ₹184 Cr in Q2 FY26 (up 81.8%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹1,711 Cr (Q1 FY26) to ₹2,603 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹2,603 Cr | ₹334 Cr | 12.8% |
| Q1 FY27 | ₹2,150 Cr | ₹172 Cr | 8.0% |
| Q4 FY26 | ₹1,848 Cr | ₹202 Cr | 10.9% |
| Q3 FY26 | ₹1,876 Cr | ₹132 Cr | 7.0% |
| Q2 FY26 | ₹1,910 Cr | ₹184 Cr | 9.6% |
| Q1 FY26 | ₹1,711 Cr | ₹154 Cr | 9.0% |
| Q4 FY25 | ₹1,770 Cr | ₹157 Cr | 8.9% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 69.87% of Alembic Pharmaceuticals Limited (Aplltd)'s shares as of Sept 2026, against 69.74% in Sept 2025 (+0.13 percentage points). Delivery averaged 49.6% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Alembic Pharmaceuticals Limited, an integrated pharmaceutical company, develops, manufactures, markets, and sells pharmaceutical products in India and internationally. The company provides products in various therapeutic areas, such as cardiology, orthopaedics, anti-diabetic, ophthalmology, gynaecology, nephrology, gastrology, urology, dermatology, anti-infective, cold and cough, and animal health; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products. Alembic Pharmaceuticals Limited was founded in 1907 and is headquartered in Vadodara, India.
1. Pharmaceuticals Business-This segment develops, manufactures, and markets pharmaceutical products.
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Glaxosmithkline Pharmaceuticals Ltd. | ₹44,982 Cr | 43.4 | 48.91% | ₹1,184 Cr | +3.3% |
| Alembic Pharmaceuticals Limited (Aplltd) | ₹20,245 Cr | 30.5 | 12.36% | ₹2,603 Cr | +11.7% |
| Bliss Gvs Pharma Ltd. | ₹6,817 Cr | 53.9 | 11.60% | ₹313 Cr | +426.3% |
| Zota Health Care Ltd | ₹4,585 Cr | n/m | -16.05% | ₹199 Cr | -15.1% |
| Amrutanjan Health Care Ltd. | ₹1,467 Cr | 25.3 | 16.62% | ₹135 Cr | -28.1% |
| Jenburkt Pharmaceuticals Ltd. | ₹433 Cr | 12.5 | 18.84% | — | -11.8% |
| Sat Kartar Life Limited | ₹256 Cr | 15.7 | 25.30% | — | — |
| Vista Pharmaceuticals Ltd. | ₹40 Cr | n/m | -10.82% | — | -37.1% |
| Welcure Drugs & Pharmaceuticals | ₹23 Cr | n/m | -5.50% | — | -64.2% |
Listed by market capitalisation. Ratios are shown for context only.
Alembic Pharmaceuticals Limited (Aplltd) is trading at ₹1,030.00, with a market capitalisation of ₹20,245 Cr.
Alembic Pharmaceuticals Limited (Aplltd) operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Non-Prescription Drugs).
Alembic Pharmaceuticals Limited (Aplltd) has a P/E of 30.5 and a return on equity of 12.36%.
Alembic Pharmaceuticals Limited (Aplltd) is listed on the NSE under the symbol APLLTD and on the BSE under the scrip code 533573.
Alembic Pharmaceuticals Limited (Aplltd)'s share price is up 11.7% over one year and up 23.9% over three months. Its 52-week range is ₹635.80 to ₹1,073.00.
In Q2 FY27, Alembic Pharmaceuticals Limited (Aplltd) reported revenue of ₹2,603 Cr and net profit of ₹334 Cr, with basic EPS of ₹17.05 (consolidated, parsed from the company's exchange filing).
Alembic Pharmaceuticals Limited (Aplltd) reported revenue of ₹2,603 Cr in Q2 FY27, up 36.3% from ₹1,910 Cr in Q2 FY26 and up 21.1% from ₹2,150 Cr in Q1 FY27.
Promoters held 69.87% of Alembic Pharmaceuticals Limited (Aplltd)'s shares as of Sept 2026, against 69.74% in Sept 2025 (+0.13 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.